URCC 22053: High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
About
This phase III trial tests whether high-dose vitamin D works in treating androgen deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers the number of falls and lessens fatigue in men getting androgen deprivation therapy.
Eligibility Criteria
Inclusion Criteria
- Be diagnosed with Stage I-IV prostate cancer without metastases to bone
- Be age 60 years or older
- Have started ADT or received their first ADT treatment in the past 3 months, with at least 6 planned months of treatment remaining
Exclusion Criteria
- Have long-term use of any pharmacologic bone-modifying agent
- Have a diagnosis of stage IV chronic kidney disease
- Have a history of hypercalcemia or vitamin D toxicity/sensitivity
Primary Investigator
Dr. Rodney Poffenberger is a board-certified urologist who has over 3 decades of clinical experience. He graduated from the University of Michigan Medical School and went on to complete his residency at Henry Ford Hospital in Detroit. Throughout the years, he has received specialized training in several different treatments, including laser surgery, cryosurgery and prostate brachytherapy, to better care for his patients. Dr. Poffenberger joined Carilion Clinic in 2022 and currently serves as the section chief of Urology.
Contact Information
Bailey Steele, MPH
Clinical Research Coordinator
